The HOPE study and diabetes. Heart Outcomes Prevention Evaluation

Comment

M W Webster. Lancet. 2000.

. 2000 Apr 1;355(9210):1181-2; author reply 1183-4.

doi: 10.1016/s0140-6736(05)72257-1.

No abstract available

Comment on

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Hansson L, et al. Lancet. 1999 Feb 20;353(9153):611-6. doi: 10.1016/s0140-6736(98)05012-0. Lancet. 1999. PMID: 10030325 Clinical Trial.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
[No authors listed] [No authors listed] Lancet. 2000 Jan 22;355(9200):253-9. Lancet. 2000. PMID: 10675071 Clinical Trial.